Revlimid (lenalidomide) - Important Safety Information from Celgene as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 09/01/2013

Problem Or Issue:
Important Safety Information communication from Celgene on the risk of hepatic disorders associated with Revlimid (lenalidomide).

Important Safety Information - Revlimid (lenalidomide)

Important Safety Information for Pharmacists- Revlimid (lenalidomide)

« Back